Depressive symptoms · people with a primary brain tumour
1 finding from 1 review
Health‐related quality of life European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ‐C30). Scale from: 0 to 100 (a higher score means a better outcome) · people with a primary brain tumour
1 finding from 1 review
Quality of life EORTC QLQ‐BN 20 · people with a primary brain tumour
1 finding from 1 review
Fatigue · people with a primary brain tumour
1 finding from 1 review
Fatigue –reduced motivation Subscale from CIS · people with a primary brain tumour
1 finding from 1 review
Cognition Symbol Digit Modalities Test (median (range)) · people with a primary brain tumour
1 finding from 1 review
Quality of life, self‐rated at post‐treatment · people with a primary brain tumour
1 finding from 1 review
Adverse events (grade ≥ 3) · people with a primary brain tumour
1 finding from 1 review
Fatigue –reduced activity Subscale from CIS · people with a primary brain tumour
1 finding from 1 review
Fatigue –severity Subscale from CIS · people with a primary brain tumour
1 finding from 1 review
Adverse events ( · people with a primary brain tumour
It is very uncertain whether boele 2013: modafinil changes adverse events ( compared with placebo (very low certainty).
1 finding from 1 review
Fatigue · people with a primary brain tumour
2 findings from 1 review
Cognition Trail Making Test A · people with a primary brain tumour
1 finding from 1 review
Cognition Trail Making Test B · people with a primary brain tumour
1 finding from 1 review
50% or greater reduction in seizure frequency · people with drug‐resistant focal epilepsy
Brivaracetam probably leads to higher 50% or greater reduction in seizure frequency (responder rate) compared with placebo (moderate certainty).
1 finding from 1 review
Seizure freedom · people with drug‐resistant focal epilepsy
Brivaracetam may leads to higher seizure freedom compared with placebo (low certainty).
1 finding from 1 review
Treatment withdrawal · people with drug‐resistant focal epilepsy
Brivaracetam showed no clear difference in treatment withdrawal compared with placebo (low certainty).
1 finding from 1 review
Withdrawals due to adverse events · people with drug‐resistant focal epilepsy
Brivaracetam may leads to higher proportion of participants who experienced adverse events leading to… compared with placebo (low certainty).
1 finding from 1 review
Adverse events as N of participants with at least one adverse event objective · people with drug‐resistant focal epilepsy
Brivaracetam showed no clear difference in proportion of participants who experienced any adverse events compared with placebo (moderate certainty).
1 finding from 1 review
Quality of life immediately after the intervention · people with Parkinson's disease
1 finding from 1 review